OBJECTIVES: Although lung transplantation is an accepted therapy for end-stage disease, recipient outcomes continue to be hindered by early primary graft dysfunction (PGD) as well as late rejection and bronchiolitis obliterans syndrome (BOS). We have previously shown that the pro-inflammatory cytokine response following transplantation correlates with the severity of PGD. We hypothesized that lung-transplant recipients with an increased inflammatory response immediately following surgery would also have a greater incidence of unfavorable long-term outcomes including rejection, BOS and ultimately death. METHODS: A retrospective study of lung-transplant recipients (n = 19) for whom serial blood sampling of cytokines was performed for 24 h following transplantation between March 2002 and June 2003 at a single institution. Long-term follow-up was examined for rejection, BOS and survival. RESULTS: Thirteen single and six bilateral lung recipients were examined. Eleven (58%) developed BOS and eight (42%) did not. Subgroup analysis revealed an association between elevated IL-6 concentrations 4 h after reperfusion of the allograft and development of BOS (P = 0.068). The correlation between IL-6 and survival time was found to be significant (corr = -0.46, P = 0.047), indicating that higher IL-6 response had shorter survival following transplantation. CONCLUSIONS: An elevation in interleukin (IL)-6 concentration immediately following lung transplantation is associated with a trend towards development of bronchiolitis obliterans, rejection and significantly decreased survival time. Further studies are warranted to confirm the correlation between the immediate inflammatory response, PGD and BOS. Identification of patients at risk for BOS based on the cytokine response after surgery may allow for early intervention.
OBJECTIVES: Although lung transplantation is an accepted therapy for end-stage disease, recipient outcomes continue to be hindered by early primary graft dysfunction (PGD) as well as late rejection and bronchiolitis obliterans syndrome (BOS). We have previously shown that the pro-inflammatory cytokine response following transplantation correlates with the severity of PGD. We hypothesized that lung-transplant recipients with an increased inflammatory response immediately following surgery would also have a greater incidence of unfavorable long-term outcomes including rejection, BOS and ultimately death. METHODS: A retrospective study of lung-transplant recipients (n = 19) for whom serial blood sampling of cytokines was performed for 24 h following transplantation between March 2002 and June 2003 at a single institution. Long-term follow-up was examined for rejection, BOS and survival. RESULTS: Thirteen single and six bilateral lung recipients were examined. Eleven (58%) developed BOS and eight (42%) did not. Subgroup analysis revealed an association between elevated IL-6 concentrations 4 h after reperfusion of the allograft and development of BOS (P = 0.068). The correlation between IL-6 and survival time was found to be significant (corr = -0.46, P = 0.047), indicating that higher IL-6 response had shorter survival following transplantation. CONCLUSIONS: An elevation in interleukin (IL)-6 concentration immediately following lung transplantation is associated with a trend towards development of bronchiolitis obliterans, rejection and significantly decreased survival time. Further studies are warranted to confirm the correlation between the immediate inflammatory response, PGD and BOS. Identification of patients at risk for BOS based on the cytokine response after surgery may allow for early intervention.
Authors: Amit Mathur; Maher Baz; E Denmark Staples; Mark Bonnell; Jerry M Speckman; Phillip J Hess; Charles T Klodell; Daniel G Knauf; Lyle L Moldawer; Thomas M Beaver Journal: Ann Thorac Surg Date: 2006-05 Impact factor: 4.330
Authors: Robert J Feezor; Henry V Baker; Wenzhong Xiao; W Anthony Lee; Thomas S Huber; Michael Mindrinos; Raymond A Kim; Laurence Ruiz-Taylor; Lyle L Moldawer; Ronald W Davis; James M Seeger Journal: J Immunol Date: 2004-06-01 Impact factor: 5.422
Authors: Jason D Christie; Martin Carby; Remzi Bag; Paul Corris; Marshall Hertz; David Weill Journal: J Heart Lung Transplant Date: 2005-06-04 Impact factor: 10.247
Authors: Elbert P Trulock; Leah B Edwards; David O Taylor; Mark M Boucek; Berkeley M Keck; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2005-08 Impact factor: 10.247
Authors: Steven M Fiser; Curtis G Tribble; Stewart M Long; Aditya K Kaza; John A Kern; David R Jones; Mark K Robbins; Irving L Kron Journal: Ann Thorac Surg Date: 2002-04 Impact factor: 4.330
Authors: Kim C Lu; Andrés Jaramillo; Rachel L Lecha; Richard B Schuessler; Aviva Aloush; Elbert P Trulock; Eric N Mendeloff; Charles B Huddleston; G Alexander Patterson; T Mohanakumar Journal: Transplantation Date: 2002-11-15 Impact factor: 4.939
Authors: Alexander S Farivar; Heather E Merry; Mauricio J Fica-Delgado; Anton S McCourtie; Brendan C Mackinnon-Patterson; Michael S Mulligan Journal: Ann Thorac Surg Date: 2006-08 Impact factor: 4.330
Authors: S M Pham; Y Yoshida; R Aeba; B G Hattler; Y Iwaki; A Zeevi; R L Hardesty; B P Griffith Journal: J Heart Lung Transplant Date: 1992 Nov-Dec Impact factor: 10.247
Authors: H Kaneda; T K Waddell; M de Perrot; X-H Bai; C Gutierrez; T Arenovich; C Chaparro; M Liu; S Keshavjee Journal: Am J Transplant Date: 2006-03 Impact factor: 8.086
Authors: P J Smith; J A Blumenthal; E P Trulock; K E Freedland; R M Carney; R D Davis; B M Hoffman; S M Palmer Journal: Am J Transplant Date: 2015-09-14 Impact factor: 8.086
Authors: Saverio La Francesca; Anthony E Ting; Jason Sakamoto; Jessica Rhudy; Nicholas R Bonenfant; Zachary D Borg; Fernanda F Cruz; Meagan Goodwin; Nicholas A Lehman; Jennifer M Taggart; Robert Deans; Daniel J Weiss Journal: Transplant Res Date: 2014-11-01